J9021 Asparaginase Erwinia Chrysanthemi (recombinant)-rywn - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Asparaginase Erwinia Chrysanthemi (recombinant)-rywn

Brand Name:

Rylaze

Strength:

0.1mg

HCPCS:

J9021

SEER*Rx Category:

Chemotherapy

Major Drug Class:

Miscellaneous Agent

Minor Drug Class:

Enzyme

Oral (Y/N):

No

FDA Approval Year:

2021

FDA Discontinuation Year:

CMS Effective Date:

Jan. 26, 2022

CMS Discontinuation Date:

Status:

In Use